Allo-APZ2-EB
( DrugBank: - / KEGG DRUG: - )
1 disease
| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 36 | 表皮水疱症 | 6 |
36. 表皮水疱症
臨床試験数 : 163 / 薬物数 : 185 - (DrugBank : 46) / 標的遺伝子数 : 50 - 標的パスウェイ数 : 125
Showing 1 to 6 of 6 trials
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2018-001009-98-IT (EUCTR) | 11/10/201920191011 | 10/11/202020201110 | Study to investigate the efficacy and safety of allo-APZ2-EB on wound healing of epidermolysis bullosa (EB) Study to investigate the efficacy and safety of allo-APZ2-EBon wound healing of epidermolysis bullos ... | An interventional, multicenter, single arm, phase I/IIa clinical trial to investigate the efficacy and safety of allo-APZ2-EB on epidermolysis bullosa (EB). - allo-APZ2-EB-II-01 An interventional, multicenter, single arm, phase I/IIa clinical trial to investigate the efficacy a ... | Recessive dystrophic epidermolysis bullosa (RDEB) MedDRA version: 20.0;Level: PT;Classification code 10014989;Term: Epidermolysis bullosa;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17] Recessive dystrophic epidermolysis bullosa (RDEB) MedDRA version: 20.0;Level: PT;Classification code ... | Product Name: allo-APZ2-EB Product Code: [allo-APZ2-EB] Other descriptive name: Allogeneic skin-derived ABCB5-positive mesenchymal stem cells Product Name: allo-APZ2-EB Product Code: [allo-APZ2-EB] Other descriptive name: Allogeneic skin-derive ... | RHEACELL GmbH & Co. KG | NULL | Not Recruiting | Female: yes Male: yes | 18 | Phase 1 | United States;France;Austria;Germany;United Kingdom;Italy | ||
| 2 | EUCTR2018-001009-98-DE (EUCTR) | 01/03/201920190301 | 03/05/201820180503 | Study to investigate the efficacy and safety of allo-APZ2-EB on wound healing of epidermolysis bullosa (EB) Study to investigate the efficacy and safety of allo-APZ2-EBon wound healing of epidermolysis bullos ... | An interventional, multicenter, single arm, phase I/IIa clinical trial to investigate the efficacy and safety of allo-APZ2-EB on epidermolysis bullosa (EB) An interventional, multicenter, single arm, phase I/IIa clinical trial to investigate the efficacy a ... | Recessive dystrophic epidermolysis bullosa (RDEB) MedDRA version: 20.0;Level: PT;Classification code 10014989;Term: Epidermolysis bullosa;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17] Recessive dystrophic epidermolysis bullosa (RDEB) MedDRA version: 20.0;Level: PT;Classification code ... | Product Name: allo-APZ2-EB Product Code: allo-APZ2-EB Other descriptive name: Allogeneic skin-derived ABCB5-positive mesenchymal stem cells Product Name: allo-APZ2-EB Product Code: allo-APZ2-EB Other descriptive name: Allogeneic skin-derived ... | RHEACELL GmbH & Co. KG | NULL | Not Recruiting | Female: yes Male: yes | 16 | Phase 1;Phase 2 | United States;France;Austria;Germany;United Kingdom;Italy | ||
| 3 | NCT03529877 (ClinicalTrials.gov) | February 16, 201920190216 | 24/4/201820180424 | Allogeneic ABCB5-positive Stem Cells for Treatment of Epidermolysis Bullosa | An Interventional, Multicenter, Single Arm, Phase I/IIa Clinical Trial to Investigate the Efficacy and Safety of Allo-APZ2-EB on Epidermolysis Bullosa (EB) An Interventional, Multicenter, Single Arm, Phase I/IIa Clinical Trial to Investigate the Efficacy a ... | Recessive Dystrophic Epidermolysis Bullosa | Biological: allo-APZ2-EB | RHEACELL GmbH & Co. KG | FGK Clinical Research GmbH;Granzer Regulatory Consulting & Services;Ticeba GmbH | Completed | 0 Years | 55 Years | All | 16 | Phase 1/Phase 2 | United States;Austria;France;Germany;United Kingdom;Italy |
| 4 | EUCTR2018-001009-98-FR (EUCTR) | 07/01/201920190107 | 30/10/201820181030 | Study to investigate the efficacy and safety of allo-APZ2-EB on wound healing of epidermolysis bullosa (EB) Study to investigate the efficacy and safety of allo-APZ2-EBon wound healing of epidermolysis bullos ... | An interventional, multicenter, single arm, phase I/IIa clinical trial to investigate the efficacy and safety of allo-APZ2-EB on epidermolysis bullosa (EB) An interventional, multicenter, single arm, phase I/IIa clinical trial to investigate the efficacy a ... | Recessive dystrophic epidermolysis bullosa (RDEB) MedDRA version: 20.0;Level: PT;Classification code 10014989;Term: Epidermolysis bullosa;System Organ Class: 10010331 - Congenital, familial and genetic disorders ;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17] Recessive dystrophic epidermolysis bullosa (RDEB) MedDRA version: 20.0;Level: PT;Classification code ... | Product Name: allo-APZ2-EB Product Code: allo-APZ2-EB Other descriptive name: Allogeneic skin-derived ABCB5-positive mesenchymal stem cells Product Name: allo-APZ2-EB Product Code: allo-APZ2-EB Other descriptive name: Allogeneic skin-derived ... | RHEACELL GmbH & Co. KG | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 18 | Phase 1;Phase 2 | United States;France;Austria;Germany;United Kingdom | ||
| 5 | EUCTR2018-001009-98-AT (EUCTR) | 05/11/201820181105 | 24/05/201820180524 | Study to investigate the efficacy and safety of allo-APZ2-EB on wound healing of epidermolysis bullosa (EB) Study to investigate the efficacy and safety of allo-APZ2-EBon wound healing of epidermolysis bullos ... | An interventional, multicenter, single arm, phase I/IIa clinical trial to investigate the efficacy and safety of allo-APZ2-EB on epidermolysis bullosa (EB) An interventional, multicenter, single arm, phase I/IIa clinical trial to investigate the efficacy a ... | Recessive dystrophic epidermolysis bullosa (RDEB) MedDRA version: 20.0;Level: PT;Classification code 10014989;Term: Epidermolysis bullosa;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17] Recessive dystrophic epidermolysis bullosa (RDEB) MedDRA version: 20.0;Level: PT;Classification code ... | Product Name: allo-APZ2-EB Product Code: allo-APZ2-EB Other descriptive name: Allogeneic skin-derived ABCB5-positive mesenchymal stem cells Product Name: allo-APZ2-EB Product Code: allo-APZ2-EB Other descriptive name: Allogeneic skin-derived ... | RHEACELL GmbH & Co. KG | NULL | Not Recruiting | Female: yes Male: yes | 16 | Phase 1;Phase 2 | United States;France;Austria;Germany;United Kingdom;Italy | ||
| 6 | EUCTR2018-001009-98-GB (EUCTR) | 18/09/201820180918 | 25/10/201820181025 | Study to investigate the efficacy and safety of allo-APZ2-EB on wound healing of epidermolysis bullosa (EB) Study to investigate the efficacy and safety of allo-APZ2-EBon wound healing of epidermolysis bullos ... | An interventional, multicenter, single arm, phase I/IIa clinical trial to investigate the efficacy and safety of allo-APZ2-EB on epidermolysis bullosa (EB) An interventional, multicenter, single arm, phase I/IIa clinical trial to investigate the efficacy a ... | Recessive dystrophic epidermolysis bullosa (RDEB) MedDRA version: 20.0;Level: PT;Classification code 10014989;Term: Epidermolysis bullosa;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17] Recessive dystrophic epidermolysis bullosa (RDEB) MedDRA version: 20.0;Level: PT;Classification code ... | Product Name: allo-APZ2-EB Product Code: allo-APZ2-EB Other descriptive name: Allogeneic skin-derived ABCB5-positive mesenchymal stem cells Product Name: allo-APZ2-EB Product Code: allo-APZ2-EB Other descriptive name: Allogeneic skin-derived ... | RHEACELL GmbH & Co. KG | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 16 | Phase 1;Phase 2 | United States;France;Austria;Germany;Italy;United Kingdom |